Language
English
Publication Date
2-4-2023
Journal
iScience
DOI
10.1016/j.isci.2023.106143
PMID
36879804
PMCID
PMC9984564
PubMedCentral® Posted Date
2-4-2023
PubMedCentral® Full Text Version
Post-Print
Abstract
Hepatocellular carcinoma (HCC) is a fatal malignant tumor, but effective clinical interventions are limited. PLGA/PEI-mediated DNA vaccine encoding the dual targets of high-mobility group box 1 (HMGB1) or GPC3 was developed for HCC treatment. Compared with PLGA/PEI-GPC3 immunization, PLGA/PEI-HMGB1/GPC3 co-immunization significantly inhibited the subcutaneous tumor growth, while increasing the infiltration of CD8
Keywords
immunology, cancer
Published Open-Access
yes
Recommended Citation
Shi, Xiaoqing; Ding, Jiage; Zheng, Yanyan; et al., "HMGB1/GPC3 Dual Targeting Vaccine Induces Dendritic Cells-Mediated CD8+T Cell Immune Response and Elicits Potential Therapeutic Effect in Hepatocellular Carcinoma" (2023). Faculty and Staff Publications. 1289.
https://digitalcommons.library.tmc.edu/baylor_docs/1289
Graphical Abstract
Included in
Diseases Commons, Epidemiology Commons, Immunology and Infectious Disease Commons, Medical Sciences Commons, Oncology Commons